Most Read Articles
20 Jun 2020
The Lundbeck Neuroscience Symposium was held at Sofitel KL Damansara over 2 days, with extensivediscussions on the management of various mental illnesses. The second day of the symposiumaddressed the topic of schizophrenia management, focusing on treatment goals, the rationale forpartial dopamine D(2) receptor agonism and the use of long-acting injectable (LAI) antipsychotics topromote adherence.
Pearl Toh, 4 days ago
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
3 days ago
Patients with psoriatic arthritis (PsA) often suffer from liver abnormalities, which are associated with higher body mass index (BMI), daily consumption of alcohol, more severe disease, and some therapies, according to a recent study.
Christina Lau, 2 days ago

Pembrolizumab in combination with chemotherapy significantly improves progression-free survival (PFS) vs chemotherapy alone in patients with previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC), results of the KEYNOTE-355 study have shown.

Escitalopram beneficial against neuroticism

02 Nov 2019

Treatment with the selective serotonin reuptake inhibitor escitalopram may confer beneficial effects on neuroticism, possibly by inducing reduction in anxiety, a recent study has shown.

Researchers reanalysed data from a randomized placebo‐controlled trial that failed to find an effect of escitalopram on neuroticism and state anxiety in a nonclinical sample to examine the drug’s unique effects on two neuroticism factors, trait anxiety and mood instability.

The study population included 80 adults free of psychiatric disorders but who had a first‐degree relative with major depression. These adults were randomized to receive escitalopram 10 mg/day or placebo for 4 weeks.

A greater reduction in the Eysenck Personality Questionnaire (EPQ) trait anxiety was observed in the escitalopram group, whereas EPQ mood instability decreased more in the placebo group, although neither difference was statistically significant.

Of note, participants in the escitalopram vs placebo group showed a greater decline in the Hamilton Anxiety Rating Scale (HAM‐A) scores, but the difference was only borderline statistically significant (p=0.09).

There was a significant interaction between baseline EPQ neuroticism and treatment condition (p=0.004), such that the effect of escitalopram on HAM‐A scores was statistically significant in participants with higher levels of EPQ trait anxiety, even after controlling for baseline HAM‐A scores.

According to the researchers, the present data could be used to guide future research on the effects of antidepressants in nonclinical populations. They underscored the need to replicate the findings in a properly designed study, given the posthoc and exploratory nature of the current analysis.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
20 Jun 2020
The Lundbeck Neuroscience Symposium was held at Sofitel KL Damansara over 2 days, with extensivediscussions on the management of various mental illnesses. The second day of the symposiumaddressed the topic of schizophrenia management, focusing on treatment goals, the rationale forpartial dopamine D(2) receptor agonism and the use of long-acting injectable (LAI) antipsychotics topromote adherence.
Pearl Toh, 4 days ago
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
3 days ago
Patients with psoriatic arthritis (PsA) often suffer from liver abnormalities, which are associated with higher body mass index (BMI), daily consumption of alcohol, more severe disease, and some therapies, according to a recent study.
Christina Lau, 2 days ago

Pembrolizumab in combination with chemotherapy significantly improves progression-free survival (PFS) vs chemotherapy alone in patients with previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC), results of the KEYNOTE-355 study have shown.